NDA 011245 · Bracco
Gastrografin
Diatrizoate Meglumine, Diatrizoate Sodium · Oral, Rectal
Last checked: Nov 20, 2026Latest source record: Aug 29, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1958
Jan 17, 1958
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
4 Phase 3, 1 recruiting
FAERS reports
372
260 serious, 54 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 4, 2021.
INDICATIONS AND USAGE Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 14, 1983 Supplement 20 · Efficacy
- Jan 17, 1958 Original approval · Type 3 - New Dosage Form
1 products under this application
- GASTROGRAFIN · DIATRIZOATE MEGLUMINE 66%; DIATRIZOATE SODIUM 10% · SOLUTION, ORAL, RECTAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Diatrizoate Meglumine" as an intervention, any sponsor and status, largest first.
- Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP PancreatitisPivotal-lookingCompleted
Abraham Mathew MDAcademic, hospital or other
NCT00953199 · 506 participants · Start Mar 2010 · Primary completion May 2013
Drug: Lidocaine Hydrochloride; Normal Saline · For: Pancreatitis
Sites: Hershey, Pennsylvania
- Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CTPivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT00478556 · 300 participants · Start Aug 2007 · Primary completion Mar 2009
Drug: Omnipaque; Gastroview · For: Healthy
Sites: Birmingham, Alabama
- Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel ObstructionPivotal-lookingCompleted
University Hospital, RouenAcademic, hospital or other
NCT00389116 · 242 participants · Start Nov 2006 · Primary completion Aug 2009
Drug: gastrograffin; water · For: Small Bowel Obstruction
Sites: Rouen, France
- Bowel Preparation Regimen for Colon Capsule Endoscopy ProcedurePivotal-lookingCompleted
Region SkaneAcademic, hospital or other
NCT05726097 · 147 participants · Start Feb 1, 2023 · Primary completion Oct 31, 2023
Drug: polyethylene glycol; sodium phosphate and 4 more · For: Colon Cancer; Inflammatory Bowel Diseases; Gastrointestinal Bleed and 1 more
Sites: Malmö, Sweden
- Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy ProcedurePivotal-lookingCompleted
Medtronic - MITGIndustry
NCT02481219 · 122 participants · Start May 2015 · Primary completion Jan 2016
Drug: Senna tablets; PEG and 5 more · For: Colorectal Cancer Screening
Sites: Anniston, Alabama; Indianapolis, Indiana; Dayton, Ohio · 6 sites in all
- Fluorescence Cholangiography During Cholecystectomy - a RCTPivotal-lookingCompleted
Hvidovre University HospitalAcademic, hospital or other
NCT02344654 · 120 participants · Start May 1, 2015 · Primary completion Aug 27, 2018
Drug: Indocyanine green; Urografin · For: Cholecystitis; Gallstones
Jinling Hospital, ChinaAcademic, hospital or other
NCT03642288 · 112 participants · Start Apr 1, 2014 · Primary completion Jun 30, 2018
Drug: Gastrografin · For: CRE-induced SBO
Nadja Haiden,MDAcademic, hospital or other
NCT01515696 · 96 participants · Start Oct 2007 · Primary completion Oct 2010
Drug: Gastrografin; Sterile water · For: Meconium Ileus; Very Low Birth Weight Infant
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria31
- diarrhoea27
- nausea24
- vomiting23
- no adverse event22
- pruritus19
- drug ineffective17
- off label use17
- dyspnoea16
- rash13
- sepsis12
- hypotension11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 9 |
| 2006 | 12 |
| 2007 | 7 |
| 2008 | 27 |
| 2009 | 15 |
| 2010 | 27 |
| 2011 | 22 |
| 2012 | 20 |
| 2013 | 17 |
| 2014 | 16 |
| 2015 | 20 |
| 2016 | 30 |
| 2017 | 22 |
| 2018 | 22 |
| 2019 | 19 |
| 2020 | 13 |
| 2021 | 25 |
| 2022 | 17 |
| 2023 | 14 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 3 |
Recalls
2 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Jun 21, 2013 · Class II · Terminated
Presence of foreign substance: One lot of the product may contain black foreign particles
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Gastrografin* (Diatrizoate Meglumine, Sodium*) · HCPCS Q9963
2024 spending
$7K
Beneficiaries
752
818 claims
Per beneficiary
$9
2024 ASP limit $0.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,616 |
| 2021 | $7,733 |
| 2022 | $8,624 |
| 2023 | $7,198 |
| 2024 | $7,027 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Systematic Review of the Clinical Presentation, Diagnosis, and Treatment of Small Bowel Obstruction.
Rami Reddy SR, Cappell MS · Curr Gastroenterol Rep 2017 · Systematic Review
- Use of water-soluble contrast medium (gastrografin) does not decrease the need for operative intervention nor the duration of hospital stay in uncomplicated acute adhesive small bowel obstruction? A multicenter, randomized, clinical trial (Adhesive Small Bowel Obstruction Study) and systematic review.
Scotté M, Mauvais F, Bubenheim M, et al. · Surgery 2017 · Multicenter Study, Randomized Controlled Trial
- Indocyanine Green Fluorescent Angiography During Laparoscopic Sleeve Gastrectomy: Preliminary Results.
Di Furia M, Romano L, Salvatorelli A, et al. · Obes Surg 2019 · Clinical Trial
- Oral water soluble contrast for the management of adhesive small bowel obstruction.
Abbas S, Bissett IP, Parry BR · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Oral water soluble contrast for the management of adhesive small bowel obstruction.
Abbas S, Bissett IP, Parry BR · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Prospective evaluation of oral gastrografin in postoperative small bowel obstruction.
Kapoor S, Jain G, Sewkani A, et al. · J Surg Res 2006 · Clinical Trial, Multicenter Study
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.